Aktie A3DAMU TRANSCENTA HOLDING LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Transcenta Holding Limited

Aktien

A3DAMU

KYG9005B1041

6628

Markt geschlossen - Hong Kong S.E.
Andere Börsenplätze
 10:09:00 03.05.2024 		% 5 Tage % 1. Jan.
1.81 HKD 0.00% Intraday Chart für Transcenta Holding Limited +1.69% -49.58%
30.04. Transcenta Holding Limited kündigt Änderungen im Vorstand und bei der Nominierung an CI
09.04. Transcenta schließt Partnerschaft mit Agilent zur Entwicklung eines Claudin18.2 Companion Diagnostic MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Transcenta Holding Limited Announces Board and Nomination Changes
Transcenta Partners with Agilent to Develop Claudin18.2 Companion Diagnostic
Transcenta Holding Limited Announces Collaboration with Agilent Technologies to Develop a Claudin18.2 Companion Diagnostic to Support TranStar301 Global Phase III Trial
Transcenta Holding Limited Reports Earnings Results for the Full Year Ended December 31, 2023
Transcenta Publishes Promising Results of Anti-Tumor Drug's Efficacy and Safety in European Journal
Transcenta Holding Limited Announces the Publication of Preclinical Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate as Potential Novel Treatment Option for Metastatic Gastric Cancer in the European Journal of Nuclear Medicine and Molecular Imaging
Transcenta Presents Data on Gastric/Gastroesophageal Cancer Treatment Trial at Spain Oncology Meet
Transcenta Holding Limited Presents Updated Efficacy Data from the Expansion Cohort of the Transtar102 of Osemitamab Plus Capox Chemotherapy Study as the First-Line Treatment of Advanced G/Gej Cancer At the ESMO Congress 2023 in Madrid, Spain
US FDA Approves Phase 3 Trial for Transcenta's Gastric Cancer Treatment
FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients
Transcenta Widens Loss in H1
Transcenta Holding Limited Announces Management Changes, Effective August 23, 2023
Transcenta Holding Limited Reports Earnings Results for the Half Year Ended June 30, 2023
Transcenta Moves to Phase II Trial of Osteoporosis Drug
Transcenta Holding Limited Receives Approval from China Center for Drug Evaluation to Initiate Phase II Clinical Trial of TST002(Blosozumab)
China, South Korea Approve Transcenta's Phase 3 Trial for Anti-Tumor Medication
Transcenta Holding Limited Receives Approval from China CDE and South Korea MFDS to Initiate Transtar301 Global Phase III Pivotal Trial of Osemitamab
Transcenta Holding Limited Presents Pfs Data by Cldn18.2 Expression Level from Phase I/Ii Study of Osemitamab Plus Capecitabine and Oxaliplatin as the First-Line Treatment of Advanced G/Gej Cancer
Transcenta Holding Limited Announces Update on Efficacy Data of Osemitamab Plus Capecitabine and Oxaliplatin
Transcenta Holding Limited commences an Equity Buyback for 10% of its issued share capital, under the authorization approved on June 9, 2023.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3DAMU Aktie
  4. Nachrichten Transcenta Holding Limited
  5. Andere Sprachen